Next Article in Journal
The Neglected Marine Fungi, Sensu stricto, and Their Isolation for Natural Products’ Discovery
Next Article in Special Issue
Development of a Mucoadhesive and In Situ Gelling Formulation Based on κ-Carrageenan for Application on Oral Mucosa and Esophagus Walls. I. A Functional In Vitro Characterization
Previous Article in Journal
Collagen Extraction Optimization from the Skin of the Small-Spotted Catshark (S. canicula) by Response Surface Methodology
Previous Article in Special Issue
Nano-in-Micro Delivery System Prepared by Co-Axial Air Flow for Oral Delivery of Conjugated Linoleic Acid
Article Menu
Issue 1 (January) cover image

Export Article

Open AccessArticle

Photo-Cured Glycol Chitosan Hydrogel for Ovarian Cancer Drug Delivery

1
Department of Biomedical Sciences, Chonnam National University Medical School, Gwangju 61469, Korea
2
Department of Surgery, Chonnam National University Medical School, Gwangju 61469, Korea
3
Department of Dental Hygiene, College of Health Sciences, Cheongju University, Cheongju 28503, Korea
4
Department of Biomedical Sciences, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea
5
Institute of Cell and Tissue Engineering, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea
*
Author to whom correspondence should be addressed.
These authors contributed equally to this study.
Mar. Drugs 2019, 17(1), 41; https://doi.org/10.3390/md17010041
Received: 27 December 2018 / Revised: 7 January 2019 / Accepted: 7 January 2019 / Published: 10 January 2019
(This article belongs to the Special Issue Marine Biopolymers and Drug Delivery)
  |  
PDF [3512 KB, uploaded 10 January 2019]
  |  

Abstract

In this study, we prepared an injectable drug delivery depot system based on a visible light-cured glycol chitosan (GC) hydrogel containing paclitaxel (PTX)-complexed beta-cyclodextrin (β-CD) (GC/CD/PTX) for ovarian cancer (OC) therapy using a tumor-bearing mouse model. The hydrogel depot system had a 23.8 Pa of storage modulus at 100 rad/s after visible light irradiation for 10 s. In addition, GC was swollen as a function of time. However, GC had no degradation with the time change. Eventually, the swollen GC matrix affected the releases of PTX and CD/PTX. GC/PTX and GC/CD/PTX exhibited a controlled release of PTX for 7 days. In addition, GC/CD/PTX had a rapid PTX release for 7 days due to improved water solubility of PTX through CD/PTX complex. In vitro cell viability tests showed that GC/CD/PTX had a lower cell viability percentage than the free PTX solution and GC/PTX. Additionally, GC/CD/PTX resulted in a superior antitumor effect against OC. Consequently, we suggest that the GC/CD system might have clinical potential for OC therapy by improving the water solubility of PTX, as PTX is included into the cavity of β-CD. View Full-Text
Keywords: injectable drug delivery depot system; visible light-cured glycol chitosan hydrogel; beta-cyclodextrin; paclitaxel; ovarian cancer therapy injectable drug delivery depot system; visible light-cured glycol chitosan hydrogel; beta-cyclodextrin; paclitaxel; ovarian cancer therapy
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Hyun, H.; Park, M.H.; Jo, G.; Kim, S.Y.; Chun, H.J.; Yang, D.H. Photo-Cured Glycol Chitosan Hydrogel for Ovarian Cancer Drug Delivery. Mar. Drugs 2019, 17, 41.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top